feedback

View Activity Materials

Funding Disclosure

This activity is supported by an educational grant from AstraZenea.

Activity Description and Educational Objectives

In this activity, based on a symposium held December 5, 2016, experts will evaluate how findings from recent clinical trials can be applied to clinical practice in order to optimise treatment of patients with advanced EGFR-mutant NSCLC.

Upon completion of this activity, participants should be better able to:
  • Describe the rationale for therapy after progression in patients with advanced EGFR-mutant NSCLC after progression on first-line therapy
  • Review the safety and efficacy associated with therapeutic options for managing advanced EGFR-mutant NSCLC after progression
  • Develop practical, evidence-based strategies for managing patients with advanced EGFR-mutant NSCLC after progression

Target Audience

This activity has been designed to meet the educational needs of oncologists involved in the management of patients with NSCLC.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

James Chih-Hsin Yang, MD, PhD
Professor & Director
Graduate Institute of Oncology
National Taiwan University
Director
Department of Oncology
National Taiwan University Hospital
Taipei, Taiwan

James Chih-Hsin Yang, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb.
Advisory Board for Astellas Pharma EMEA; Bayer Plc; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene Ltd; Clovis Oncology; Eli Lilly and Company; Merck Serono; Merrimack Pharmaceuticals; MSD; Novartis; Ono Pharmaceutical Co Ltd; Pfizer Inc; Roche/Genentech; and Yuhan Pharmaceuticals.

Faculty

Anders Mellemgaard, MD, PhD
Department of Oncology
Copenhagen University Hospital
Herlev, Denmark

Anders Mellemgaard, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Boehringer Ingelheim; and Eli Lilly and Company.
Advisory Board for Astra Zeneca; Boehringer Ingelheim; and MSD.

Howard (Jack) West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Founder and President
Global Resource for Advancing Cancer Education (GRACE)
Seattle, Washington, USA

Howard (Jack) West, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma EMEA; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; and Guardant Health Trovagene.
Advisory Board for Astellas Pharma EMEA; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; and Guardant Health Trovagene.

PeerVoice Medical Director

Annette Wiggins has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: December 30, 2016 - December 29, 2017
Time to Complete: 60 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

For technical assistance, please contact us.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.